Posted by on February 13, 2018 8:14 pm
Categories: Crispr Articles

Source: CRISPR – Fast Initial Growth, But Long-Term Revenues Will Depend on “Wins”

ROCKVILLE, Md., Feb. 13, 2018 /PRNewswire/ — New York City-based market research firm Kalorama Information projects fast revenue growth for the most important gene editing technology CRISPR/Cas9 –  33.7% growth over the next five years, as revenues grow from $779 million in 2017 to $5.2 billion in 2023.  

But Kalorama said the technology revenue growth will slow during that period from its current breakneck pace, and novelty growth will be proved in the marketplace by winning applications.   The finding was made in Kalorama Information’s report: The Market and Potential for CRISPR/Cas9 Gene Editing.

“It’s a technology that can be used for a broad group of applications – drugs to food to disease research,” said Bruce Carlson, Publisher of Kalorama Information.  “A lot of customers is always a good sign for a market.  That being said, growth is not without limits and we will watch over the next five years how many wins the technology can score in real-world applications”

The CRISPR-Cas9 gene editing systems consist of a short, non-coding RNA molecule as the DNA binding domain, and a Cas9 enzyme having DNA-cleaving function.  The RNA molecule also has the role of guiding the Cas9 enzyme to the targeted genomic location, which is typically 20 nucleotides in length. Cas9 is the protein that makes gene-editing work.  Basically, Cas9 helps to snip out a piece of DNA at any point in an organism—including, for instance, viral or faulty DNA—and then enables the cell to stitch the ends back together.

CRISPR screening is being applied to numerous aspects of functional genomics, including transcription factors, non-coding RNAs and protein-protein interactions, especially in cancer cells.  Kalorama Information said to watch for developments in biodrugs or other areas as a result of CRISPR/Cas9 for an indication of whether brisk investments will continue.

The report said market will be a larger factor in North America and Europe, with over 70% of revenues, but other markets will demonstrate faster revenue growth for a longer period.   Agilent, GE Healthcare, Thermo Fischer, Gene Script, CRISPR Therapeutics and Precision Biosciences are leaders in the market.

Developments in CRISPR, market projections and forecasts, and company partnership information is covered in Kalorama Information’s report.  Kalorama also covers markets for biotech instrumentation, next-generation sequencing, molecular testing systems and reagents, biosimilar drugs and several other recent topics in large market research studies.  The companies biotechnology reports can be found at:

About Kalorama Information

Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama’s website and are also available on and  

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Press Contact:
Bruce Carlson
212 807 2262  

SOURCE Kalorama Information

Published at Tue, 13 Feb 2018 20:03:04 +0000

Leave a Reply